EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 020)

Dees, Elizabeth Claire

Abstract

- Early Phase Clinical Research Support (EPCRS) The Early Phase Clinical Research Support (EPCRS) provides critical resources for innovative short duration research protocols at UNC Lineberger Comprehensive Cancer Center (LCCC) in the form of skilled and specialized research coordinator, data management, and laboratory support. The trials supported by this resource are: complex with strong correlative science and/or pharmacokinetic and pharmacodynamic components; LCCC investigator-initiated; and primarily based on scientific expertise and interests of LCCC members. Trials are selected from among those submitted to the Protocol Office Executive Committee for review. Dr Claire Dees, EPCRS Faculty Director and co-leader, Clinical Research Program, in direct consultation with Drs. Carey (Associate Director, Clinical Sciences) and Hayes (co-leader, Clinical Research Program), makes the final selection. LCCC members conducted numerous innovative studies over the last five years including those: evaluating novel compounds with radiation; involving novel combinations; and incorporating novel correlative biomarkers and imaging. Many ECPRS supported trials originated in basic and preclinical science in UNC Lineberger laboratories. Since 2010, LCCC recruited a number of talented investigators actively growing our Phase I investigator initiated trial portfolio and so we anticipate expanded ECPRS use. In addition, the inaugural trials of the UNC immunotherapy center will begin in this cycle and will require additional specialized support. The first patients will be enrolled on UNC immunotherapy trials in the spring of 2016 and these initial trials would include patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and multiple myeloma. The strong commitment of the UNC Lineberger leadership to the development of novel therapeutics as a Cancer Center strategic direction creates an environment that will generate even greater demand for specialized support.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Center Core Grants (P30)
• Project #: 2P30CA016086-40
• Application #: 8999674
• Study Section: Subcommittee I - Transistion to Independence (NCI)
• Budget Start: 2016-03-24
• Budget End: 2016-11-30
• Support Year: 40
• Fiscal Year: 2016

Institution

• Name: University of North Carolina Chapel Hill
• DUNS #: 608195277
• City: Chapel Hill
• State: NC
• Country: United States
• Zip Code: 27599

Publications

Kolupaev, Oleg V; Dant, Trisha A; Bommiasamy, Hemamalini et al. (2018) Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. Blood Adv 2:2307-2319

Beckford Vera, Denis R; Smith, Christof C; Bixby, Lisa M et al. (2018) Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS One 13:e0193832

McLamarrah, Tiffany A; Buster, Daniel W; Galletta, Brian J et al. (2018) An ordered pattern of Ana2 phosphorylation by Plk4 is required for centriole assembly. J Cell Biol 217:1217-1231

Sanoff, Hanna K (2018) Best Evidence Supports Annual Surveillance for Resected Colorectal Cancer. JAMA 319:2083-2085

Chiou, Yi-Ying; Hu, Jinchuan; Sancar, Aziz et al. (2018) RNA polymerase II is released from the DNA template during transcription-coupled repair in mammalian cells. J Biol Chem 293:2476-2486

Kwo, Paul; Fried, Michael W; Reddy, K Rajender et al. (2018) Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. Hepatol Commun 2:354-363

Dunn, Julia L M; Kartchner, Laurel B; Gast, Karli et al. (2018) Mammalian target of rapamycin regulates a hyperresponsive state in pulmonary neutrophils late after burn injury. J Leukoc Biol 103:909-918

Xiao, Weidong; Gao, Guangping; Ling, Chen et al. (2018) Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates. Nat Med 24:699

Zhang, Xintao; He, Ting; Chai, Zheng et al. (2018) Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration. Biomaterials 176:71-83

Wang, Sheng; Che, Tao; Levit, Anat et al. (2018) Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature 555:269-273